Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data.

Rafferty MR, Schmidt PN, Luo ST, Li K, Marras C, Davis TL, Guttman M, Cubillos F, Simuni T; all NPF-QII Investigators..

J Parkinsons Dis. 2016 Nov 14. [Epub ahead of print]

PMID:
27858719
2.

Laughter is the best medicine: The Second City® improvisation as an intervention for Parkinson's disease.

Bega D, Palmentera P, Wagner A, Hovde M, Barish B, Kwasny MJ, Simuni T.

Parkinsonism Relat Disord. 2016 Nov 5. pii: S1353-8020(16)30432-1. doi: 10.1016/j.parkreldis.2016.11.001. [Epub ahead of print]

PMID:
27836715
3.

Altered premotor cortical oscillations during repetitive movement in persons with Parkinson's disease.

Stegemöller EL, Allen DP, Simuni T, MacKinnon CD.

Behav Brain Res. 2017 Jan 15;317:141-146. doi: 10.1016/j.bbr.2016.09.036.

PMID:
27641326
4.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K; PPMI Investigators..

Ann Clin Transl Neurol. 2016 May 17;3(7):482-94. doi: 10.1002/acn3.317.

5.

How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?

Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators..

Parkinsonism Relat Disord. 2016 Jul;28:62-7. doi: 10.1016/j.parkreldis.2016.04.027.

PMID:
27132498
6.

Technology in Parkinson's disease: Challenges and opportunities.

Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology..

Mov Disord. 2016 Sep;31(9):1272-82. doi: 10.1002/mds.26642. Review.

PMID:
27125836
7.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative..

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2.

PMID:
27021906
8.

Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease.

Nowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D.

Mov Disord. 2016 May;31(5):725-33. doi: 10.1002/mds.26546. Review.

PMID:
26919664
9.

Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.

Kianirad Y, Simuni T.

Curr Neurol Neurosci Rep. 2016 Apr;16(4):34. doi: 10.1007/s11910-016-0635-8. Review.

PMID:
26898686
10.
11.

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(4):993. doi: 10.3233/JPD-159002. No abstract available.

PMID:
26683786
12.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.

Bega D, Kim S, Zhang Y, Elm J, Schneider J, Hauser R, Fraser A, Simuni T.

J Parkinsons Dis. 2015;5(4):773-82. doi: 10.3233/JPD-150668.

PMID:
26639661
13.

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B; NINDS NET-PD Investigators..

J Parkinsons Dis. 2015;5(4):731-6. doi: 10.3233/JPD-150666.

14.

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(3):621. doi: 10.3233/JPD-159001. No abstract available.

PMID:
26406143
15.

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators..

Mov Disord. 2016 Jan;31(1):86-94. doi: 10.1002/mds.26373.

PMID:
26293177
16.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators..

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7.

17.

Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).

Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB; Parkinson's Progression Marker Initiative (PPMI) investigators..

Mov Disord. 2016 Jan;31(1):79-85. doi: 10.1002/mds.26374.

PMID:
26268663
18.

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.

Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi K, Poewe W, Mollenhauer B, Knake S, Mari Z, McCoy A, Ranola M, Marek K.

Mov Disord. 2015 Dec;30(14):1885-92. doi: 10.1002/mds.26325.

PMID:
26260437
19.

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators..

Lancet Neurol. 2015 Aug;14(8):795-803. doi: 10.1016/S1474-4422(15)00144-1. Erratum in: Lancet Neurol. 2015 Oct; 14(10):979.

20.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Högl B, Postuma R, Videnovic A, Amara AW, Marek K; PPMI Sleep Working group on behalf of the PPMI Investigators..

Mov Disord. 2015 Sep;30(10):1371-81. doi: 10.1002/mds.26248.

Items per page

Supplemental Content

Loading ...
Support Center